^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Clear Cell Renal Cell Carcinoma
    Drug:Inlyta (axitinib) (VEGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    02/03/2021
    Excerpt:
    First-line therapy for clear cell histology: Useful in certain circumstances…Axitinib (category 2B).